{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:18:29Z","timestamp":1792653509966,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide a human-relevant platform for cardiac function assessment. Alternative assays using hiPSC-CMs are increasingly being employed for regulatory decision-making. A retrospective review revealed steady use of hiPSC-CM-based in vitro assays in nonclinical studies of drug-induced cardiotoxicity in regulatory submissions to the U.S. Food and Drug Administration (FDA). Most of the hiPSC-CMs data were obtained in exploratory studies and submitted as supportive evidence in concordance with other nonclinical data. Some of those studies were used to inform clinical trial design. This article provides an overview of the use of hiPSC-CMs in regulatory applications to FDA, with a focus on the integration of human-relevant in vitro data into proarrhythmic and non-proarrhythmic risk assessment. By identifying the regulatory submissions including hiPSC-CMs data, we explore their utility and discuss their limitations for predicting human cardiac safety in clinical trials. An important take-home message is that regulatory acceptance of hiPSC-CMs data is dependent on both the context of use and accurate data interpretation.<\/jats:p>","DOI":"10.1093\/toxsci\/kfac095","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T16:07:36Z","timestamp":1662998856000},"page":"117-126","source":"Crossref","is-referenced-by-count":62,"title":["Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3427-0565","authenticated-orcid":false,"given":"Xi","family":"Yang","sequence":"first","affiliation":[{"name":"Division of Pharmacology & Toxicology, Office of Cardiology, Hematology, Endocrinology, & Nephrology, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, Maryland 20903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre J S","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, Maryland 20903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0212-2090","authenticated-orcid":false,"given":"Li","family":"Pang","sequence":"additional","affiliation":[{"name":"Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration , Jefferson, Arizona 72079, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-3297","authenticated-orcid":false,"given":"David G","family":"Strauss","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, Maryland 20903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"2022112807594711300_kfac095-B1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/toxsci\/kfw135","article-title":"Effects of bms-986094, a guanosine nucleotide analogue, on mitochondrial DNA synthesis and function","volume":"153","author":"Baumgart","year":"2016","journal-title":"Toxicol. Sci"},{"key":"2022112807594711300_kfac095-B2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation-contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"2022112807594711300_kfac095-B3","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Rep"},{"key":"2022112807594711300_kfac095-B4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cts.12674","article-title":"Clinical trial in a dish: Personalized stem cell-derived cardiomyocyte assay compared with clinical trial results for two QT-prolonging drugs","volume":"12","author":"Blinova","year":"2019","journal-title":"Clin. Transl. Sci"},{"key":"2022112807594711300_kfac095-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-76052-y","article-title":"Human perinatal stem cell derived extracellular matrix enables rapid maturation of hiPSC-CM structural and functional phenotypes","volume":"10","author":"Block","year":"2020","journal-title":"Sci. Rep"},{"key":"2022112807594711300_kfac095-B6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/toxsci\/kfz235","article-title":"Detection of drug-induced Torsades de Pointes arrhythmia mechanisms using hiPSC-Cm syncytial monolayers in a high-throughput screening voltage sensitive dye assay","volume":"173","author":"da Rocha","year":"2020","journal-title":"Toxicol. Sci"},{"key":"2022112807594711300_kfac095-B7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev-pharmtox-010919-023309","article-title":"Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell-derived cardiomyocytes: Fit for purpose or forever elusive?","volume":"60","author":"de Korte","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol"},{"key":"2022112807594711300_kfac095-B8","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.bbamcr.2015.10.014","article-title":"Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform","volume":"1863","author":"Denning","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"2022112807594711300_kfac095-B9","author":"FDA","year":"2015"},{"key":"2022112807594711300_kfac095-B10","author":"FDA","year":"2022"},{"key":"2022112807594711300_kfac095-B11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/toxsci\/kfw211","article-title":"From the cover: Investigative nonclinical cardiovascular safety and toxicology studies with BMS-986094, an NS5b RNA-dependent RNA polymerase inhibitor","volume":"155","author":"Gill","year":"2017","journal-title":"Toxicol. Sci"},{"key":"2022112807594711300_kfac095-B12","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1161\/RES.0000000000000291","article-title":"Use of human induced pluripotent stem cell\u2013derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: A scientific statement from the American Heart Association","volume":"125","author":"Gintant","year":"2019","journal-title":"Circ. Res"},{"key":"2022112807594711300_kfac095-B13","doi-asserted-by":"crossref","first-page":"104756","DOI":"10.1016\/j.yrtph.2020.104756","article-title":"Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations","volume":"117","author":"Gintant","year":"2020","journal-title":"Regul. Toxicol. Pharmacol"},{"key":"2022112807594711300_kfac095-B14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.14573\/altex.1805301","article-title":"A human population-based organotypic in vitro model for cardiotoxicity screening","volume":"35","author":"Grimm","year":"2018","journal-title":"ALTEX"},{"key":"2022112807594711300_kfac095-B15","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fphar.2019.00884","article-title":"Considerations for an in vitro, cell-based testing platform for detection of adverse drug-induced inotropic effects in early drug development. Part 1: General considerations for development of novel testing platforms","volume":"10","author":"Guth","year":"2019","journal-title":"Front Pharmacol"},{"key":"2022112807594711300_kfac095-B16","first-page":"25","article-title":"Evaluation of batch variations in induced pluripotent stem cell-derived human cardiomyocytes from 2 major suppliers","volume":"156","author":"Huo","year":"2017","journal-title":"Toxicol. Sci"},{"key":"2022112807594711300_kfac095-B17","author":"ICH","year":"2020"},{"key":"2022112807594711300_kfac095-B18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","article-title":"The pathophysiology of heart failure","volume":"21","author":"Kemp","year":"2012","journal-title":"Cardiovasc. Pathol"},{"key":"2022112807594711300_kfac095-B19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCRESAHA.112.300567","article-title":"Induced pluripotent stem cell-derived cardiomyocytes: Boutique science or valuable arrhythmia model?","volume":"112","author":"Knollmann","year":"2013","journal-title":"Circ. Res"},{"key":"2022112807594711300_kfac095-B20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.taap.2016.08.006","article-title":"Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells","volume":"308","author":"Lagrutta","year":"2016","journal-title":"Toxicol. Appl. Pharmacol"},{"key":"2022112807594711300_kfac095-B21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/1091581816683642","article-title":"In vitro metabolite formation in human hepatocytes and cardiomyocytes and metabolism and tissue distribution in monkeys of the 2'-c-methylguanosine prodrug BMS-986094","volume":"36","author":"Li","year":"2017","journal-title":"Int. J. Toxicol"},{"key":"2022112807594711300_kfac095-B22","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1111\/bph.14047","article-title":"Nonclinical cardiovascular safety of pitolisant: Comparing international conference on harmonization S7B and comprehensive in vitro pro-arrhythmia assay initiative studies","volume":"174","author":"Ligneau","year":"2017","journal-title":"Br. J. Pharmacol"},{"key":"2022112807594711300_kfac095-B23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12015-019-09935-x","article-title":"Advances in pluripotent stem cells: History, mechanisms, technologies, and applications","volume":"16","author":"Liu","year":"2020","journal-title":"Stem Cell Rev. Rep"},{"key":"2022112807594711300_kfac095-B24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0960327115592939","article-title":"Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys","volume":"35","author":"Luo","year":"2016","journal-title":"Hum. Exp. Toxicol"},{"key":"2022112807594711300_kfac095-B25","first-page":"712","article-title":"The long and winding road of cardiomyocyte maturation","author":"Maroli","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2022112807594711300_kfac095-B26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/toxsci\/kfw153","article-title":"Identification of drug-drug interactions in vitro: A case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes","volume":"154","author":"Millard","year":"2016","journal-title":"Toxicol. Sci"},{"key":"2022112807594711300_kfac095-B27","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/med.21476","article-title":"Comprehensive review of cardiovascular toxicity of drugs and related agents","volume":"38","author":"Mlad\u011bnka","year":"2018","journal-title":"Med. Res. Rev"},{"key":"2022112807594711300_kfac095-B28","volume-title":"Heart Physiology: From Cell to Circulation","author":"Opie","year":"2004"},{"key":"2022112807594711300_kfac095-B29","doi-asserted-by":"crossref","first-page":"e32-69","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"2022112807594711300_kfac095-B30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cotox.2020.04.001","article-title":"Toxicity testing in the era of iPSC: A perspective regarding the use of patient-specific iPSC-CMs for cardiac safety evaluation","volume":"23\u201324","author":"Pang","year":"2020","journal-title":"Curr. Opin. Toxicol"},{"key":"2022112807594711300_kfac095-B31","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCRESAHA.119.315378","article-title":"Workshop report: FDA workshop on improving cardiotoxicity assessment with human-relevant platforms","volume":"125","author":"Pang","year":"2019","journal-title":"Circ. Res"},{"key":"2022112807594711300_kfac095-B32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28752","article-title":"Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys","volume":"64","author":"Regan","year":"2016","journal-title":"Hepatology"},{"key":"2022112807594711300_kfac095-B33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3389\/fphar.2019.00934","article-title":"Considerations for an in vitro, cell-based testing platform for detection of drug-induced inotropic effects in early drug development. Part 2: Designing and fabricating microsystems for assaying cardiac contractility with physiological relevance using human iPSC-cardiomyocytes","volume":"10","author":"Ribeiro","year":"2019","journal-title":"Front Pharmacol"},{"key":"2022112807594711300_kfac095-B34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium","volume":"167","author":"Sager","year":"2014","journal-title":"Am. Heart J"},{"key":"2022112807594711300_kfac095-B35","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cvr\/cvz024","article-title":"Personalized medicine in cardio-oncology: The role of induced pluripotent stem cell","volume":"115","author":"Sayed","year":"2019","journal-title":"Cardiovasc. Res"},{"key":"2022112807594711300_kfac095-B36","doi-asserted-by":"crossref","first-page":"3920195","DOI":"10.1155\/2017\/3920195","article-title":"A review of the molecular mechanisms underlying the development and progression of cardiac remodeling","volume":"2017","author":"Schirone","year":"2017","journal-title":"Oxid. Med. Cell. Longev"},{"key":"2022112807594711300_kfac095-B37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/hh0901.090298","article-title":"Cardiac Na(+)-Ca(2+) exchange: Molecular and pharmacological aspects","volume":"88","author":"Shigekawa","year":"2001","journal-title":"Circ. Res"},{"key":"2022112807594711300_kfac095-B38","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cphy.c140054","article-title":"Assessment of cardiac function\u2013basic principles and approaches","volume":"5","author":"Spinale","year":"2015","journal-title":"Compr. Physiol"},{"key":"2022112807594711300_kfac095-B39","author":"Strauss","year":"2022"},{"key":"2022112807594711300_kfac095-B40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/2168479018795117","article-title":"Comprehensive in vitro proarrhythmia assay (CiPA) update from a Cardiac Safety Research Consortium\/Health and Environmental Sciences Institute\/FDA meeting","volume":"53","author":"Strauss","year":"2019","journal-title":"Ther. Innov. Regul. Sci"},{"key":"2022112807594711300_kfac095-B41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin. Pharmacol. Ther"},{"key":"2022112807594711300_kfac095-B42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin. Pharmacol. Ther"},{"key":"2022112807594711300_kfac095-B43","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.cmet.2017.04.025","article-title":"Molecular mechanisms underlying cardiac adaptation to exercise","volume":"25","author":"Vega","year":"2017","journal-title":"Cell Metab"},{"key":"2022112807594711300_kfac095-B44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial determinants of doxorubicin-induced cardiomyopathy","volume":"126","author":"Wallace","year":"2020","journal-title":"Circ. Res"},{"key":"2022112807594711300_kfac095-B45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2018.06.005","article-title":"CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion","volume":"93","author":"Wallis","year":"2018","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2022112807594711300_kfac095-B4867444","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/toxsci\/kfac043","article-title":"Effects of serum and compound preparation methods on delayed repolarization evaluation with human iPSC-CMs","volume":"188","author":"Wei","year":"2022","journal-title":"Toxicol. Sci."},{"key":"2022112807594711300_kfac095-B46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/CIRCRESAHA.114.300558","article-title":"Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes","volume":"114","author":"Yang","year":"2014","journal-title":"Circ. Res"},{"key":"2022112807594711300_kfac095-B47","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1161\/CIRCRESAHA.117.311080","article-title":"Induced pluripotent stem cells 10 years later: For cardiac applications","volume":"120","author":"Yoshida","year":"2017","journal-title":"Circ. Res"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfac095\/45983349\/kfac095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/190\/2\/117\/47233660\/kfac095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/190\/2\/117\/47233660\/kfac095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T03:00:13Z","timestamp":1669604413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/190\/2\/117\/6696723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfac095","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,9,13]]}}}